Publications by authors named "J Riedel"
Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide, requiring innovative therapeutic strategies. This project explores a nano-pharmaceutical approach to enhance the efficacy of cardiovascular drugs, focusing on carvedilol and curcumin. These agents, known for their potential cardiovascular benefits, are encapsulated within Soluplus® micelles to form a novel drug delivery system.
View Article and Find Full Text PDFWe used electrospray ionization and ion mobility spectrometry-mass spectrometry to detect and characterize the three anticancer drugs palbociclib, copanlisib, and olaparib. Ion mobility-mass spectrometry and density functional theory revealed that these compounds generate isomers during ionization (protomers) due to the presence of multiple protonation sites within their chemical structures. Our work has implications for understanding the solution- and gas-phase chemistry of these molecules during spray-based ionization processes.
View Article and Find Full Text PDFBackground: Respiratory syncytial virus (RSV) is a common cause for severe lower respiratory tract infections (LRTI) in children < 2 years of age in Germany - though little is known about the clinical and economic burden of RSV in children with and without risk factors per month of life.
Methods: In a retrospective health claims analysis, we identified RSV inpatient cases between 2014 and 2019. We assessed incidence rates, mortality rate, healthcare resource utilization, associated direct costs per case and excess costs for 30, 90 and 365 days after hospital admission matched to a control group.
Article Synopsis
- ANCA-associated vasculitis is a severe autoimmune disease that can lead to kidney failure due to crescentic glomerulonephritis, and current treatments using non-specific immunosuppressive drugs may be insufficient and carry risks.
- Researchers analyzed kidney samples from 34 patients with ANCA-GN and identified specific inflammatory T cells that contribute to the disease, leading to the discovery of ustekinumab as a promising targeted treatment.
- In a trial, four patients with recurring ANCA-GN treated with ustekinumab and low-dose cyclophosphamide showed significant improvement in kidney function and overall health, indicating potential for this approach to be further explored in clinical settings.